Background: The outcome of bullous pemphigoid (BP), the most frequent autoimmune skin-blistering disease, involves matrix metalloproteinase 9 (MMP-9), IL-17, and IL-23 release from infiltrated inflammatory cells. The chemokine CXCL10 has been associated with several autoimmune diseases, but its participation in BP pathophysiology still needs to be clarified. Objective: We sought to assess whether BP outcome was associated with different CXCL10 levels and to evaluate the contribution of CXCL10 to the described cytokine/protease inflammatory loop associated with disease outcome. Methods: Skin biopsy specimens (n 5 16), serum (n 5 114), blister fluid (n 5 23), and primary inflammatory cells from patients with BP were used to investigate CXCL10 expression and function. Results: At baseline, both resident cells, such as keratinocytes and fibroblasts, and infiltrating immune cells expressed CXCL10 at lesional sites in skin of patients with BP. CXCL10 levels were higher in blister fluid (P < .0001) and serum (P < .005) from patients with BP than in serum from age-and sex-matched control subjects (n 5 34). Furthermore, CXCL10 serum levels increased at day 60 only in patients who relapsed within the first year of treatment (n 5 33, P < .005). Interestingly, CXCL10 expression could be upregulated by itself and IL-17 in inflammatory cells. Notably, neutrophils and
Bullous pemphigoid (BP) is the most common autoimmune subepidermal blistering disease. The disease typically occurs in the elderly, with a generalized pruritic bullous eruption. Although most cases of BP are rapidly controlled by therapy, approximately 30% of patients experience disease relapse within the first year of follow-up. 1 Recently, a panel of experts elaborated recommendations to evaluate disease activity at the time of diagnosis and therapeutic response. 2 However, there is currently no tool available to predict disease outcome.
BP is associated with BP180/BP230 autoantibody production. After a few weeks of treatment with either systemic or superpotent topical corticosteroids, patients with BP are cleared of all clinical symptoms or signs while anti-BP180 autoantibody serum levels are still high. 1, 3, 4 Recently, we showed that not only serum autoantibody titers but also the serum concentration of cytokines belonging to the IL-17 axis varied differently in patients with BP with ongoing remission or in patients with BP who relapsed during the first year of treatment, 1, 5, 6 suggesting that immunologic and biological parameters could help clinicians predict BP relapse. Here, we aimed at further extending this notion, with the ultimate goal to later elaborate a useful and practical score associated with disease outcome.
BP flares are associated with skin alterations induced by the binding of autoantibodies to proteins of the hemidesmosome, which further triggers the inflammatory pathophysiologic process leading to dermal-epidermal junction cleavage and, subsequently, to blister formation. The role of inflammatory cells and molecules in this process has been largely demonstrated with the use of animal models. [7] [8] [9] In addition, the importance of the inflammatory response in patients with BP was further evidenced by the presence of large amounts of cytokines in serum and blister fluid from patients with BP. 10 Release of cytokines at skin lesional sites requires both recruitment and activation of inflammatory cells. In this line CXCL10, a chemoattractant molecule for several inflammatory cells, 11 was shown to be expressed in serum from patients with BP. 12 Interestingly, CXCL10 levels in the serum of patients with BP significantly increased with disease severity, 12 which is in line with the fact that high CXCL10 levels in the peripheral fluid are considered a marker of host immune response in both patients with organ-specific and those with systemic autoimmune diseases. 11, 13, 14 Therefore serum CXCL10 expression might be of importance because it could reflect important production of this potent chemoattractant for inflammatory cells at the site of the lesion. In addition to its chemotactic effects, CXCL10, which is expressed not only by inflammatory immune cells, such as lymphocytes, monocytes, and neutrophils, but also by resident cell types involved in skin architecture, such as keratinocytes, fibroblasts, and endothelial cells, 11, 13, 14 has several other functions through activation of its receptor, CXCR3, which could either expand an autoaggressive immune response or facilitate tissue regeneration. 15, 16 However, the implications of CXCL10 in the pathophysiologic process of BP and as a potential marker of BP relapse have not been investigated.
Subepidermal blister formation depends on proteinases released by infiltrating inflammatory cells. [17] [18] [19] [20] Within BP blister fluids, matrix metalloproteinase 9 (MMP-9) and neutrophil elastase are key proteinases in the pathologic process associated with BP, although other proteinases are also involved in the proteolytic cascade. 5, 18, [21] [22] [23] [24] [25] [26] [27] In addition, MMP-9 is also a key molecule involved in the infiltration of inflammatory cells. 28 Although the binding of CXCL10 onto its receptors, CXCR3A and CXCR3B, regulates immune responses through the recruitment and activation of leukocytes, such as lymphocytes, eosinophils, monocytes, and neutrophils, the main infiltrated cells observed in the lesional skin of patients with BP, [29] [30] [31] its involvement in MMP-9 secretion from these cells has still not been investigated.
In the present study we investigated CXCL10 expression at the site of lesions and in biological fluids (serum and blister fluid) in patients with BP and assessed CXCL10 clinical involvement by performing a longitudinal study of serum CXCL10 concentrations with respect to outcome in patients with BP. The link between the presence of CXCL10 and other inflammatory molecules (particularly IL-17) was further examined in serum according to outcomes in patients with BP. Finally, we investigated the influence of CXCL10 in the protease-mediated autoinflammatory response associated with BP and initiated a novel strategy to potentially control this response by using a new nonsteroidal potential therapeutic agent mimicking corticosteroids.
METHODS

Study patients and design
This prospective, multicenter, observational, and translational study was conducted in 8 French Dermatology departments, among which 3 belong to the French Referral Center for Autoimmune Bullous Diseases (Reims, Rouen, and Limoges). Consecutive patients with newly diagnosed BP were included based on the following criteria: clinical features typical of BP with the presence of at least 3 of 4 well-established criteria by Vaillant et al, 32 subepidermal blistering on skin biopsy, and deposits of IgG, C3, or both in a linear pattern along the epidermal basement membrane zone determined by means of direct immunofluorescence. Among the 122 patients with BP included, 31 consecutive patients with BP were enrolled in the Dermatology Department of the Reims University Hospital from 2009 to 2011 (8 men and 23 women; mean age, 80.8 years; range, 53-96 years). For these patients, blister fluid was collected at the time of diagnosis, when possible. The study was approved by the Ethics Committee of the University Hospital of Reims (institutional review board; 04/14/2009); patients or their relatives received an information letter and provided oral consent. Serum samples from age-and sex-matched patients without inflammatory and autoimmune diseases admitted to the trauma department of the Reims University Hospital were used as control subjects. All voluntary subjects provided written informed consent before inclusion in the study.
Cell isolation and cell culture
The THP-1 monocytic cell line, kindly provided by Dr S. Hart from the University of Edinburgh, United Kingdom, was cultured in RPMI 1640 medium (Life Technologies, Grand Island, NY) supplemented with 10% FBS, 2 mmol/L glutamine, 25 U/mL penicillin, and 25 U/mL streptomycin at 378C in a humidified 5% CO 2 incubator. PBMCs and PMN cells from control subjects or patients with BP were obtained by means of density gradient centrifugation from EDTA-treated whole blood by using a density gradient medium (GranuloSep; Eurobio-Abcys, Courtaboeuf, France). Monocytes were purified from PBMCs by means of positive selection with CD14 immunomagnetic beads (MACS; Miltenyi Biotec, Bergisch Gladbach, Germany), according to the manufacturer's instructions. Flow through was then used to isolate T lymphocytes by means of negative selection with the Pan T-cell Isolation Kit from Miltenyi Biotec (MACS). All leukocytes were cultured in RPMI 1640 medium (Life Technologies), 2 mmol/L glutamine, 25 U/mL penicillin, and 25 U/mL streptomycin at 378C in a humidified 5% CO 2 incubator. Monocytes were differentiated into macrophages by culturing them for 7 days in the presence of autologous serum (10%).
Freshly isolated lymphocytes and monocytes from patients with BP and monocyte-derived macrophages from patients with BP were stimulated for 3 hours with IL-17, IL-23, or CXCL10 (1 ng/mL). Cells were then harvested, and CXCL10 gene expression was analyzed. For MMP-9 expression analysis, isolated leukocytes from healthy donors and patients with BP and THP-1 cells were cultured in FBS-free medium and stimulated overnight (PBMCs, lymphocytes, and monocytes) or for 1 hour (PMNs) with CXCL10 (500 pg/mL). Cells and culture media were harvested and analyzed for gene expression and signaling pathway activation and MMP-9 secretion respectively. When indicated, the pharmacologic inhibitors U0126 (Promega, Madison, Wis), LY294002, and SN50 (Merck Millipore, Darmstadt, Germany) and SB203580 (Sigma, St Louis, Mo), methylprednisolone (Sigma), and compound A 33 were introduced 1 hour before stimulation. All experiments were performed at least 3 times. To mimic in vivo conditions, freshly isolated PBMCs from healthy subjects were cultured in RPMI medium at a concentration of 2 3 10 6 cells/mL with 25% blister fluid (BF) for 24 hours consecutively to a stimulation with either 25% autologous serum or 25% serum from patients with BP for 24 hours before harvest for CXCL10 gene expression analysis (n 5 5). Control PBMCs were cultured at a concentration of 2 3 10 6 cells/mL with either 25% autologous serum or BP serum alone.
Gene expression analysis
Total RNA from isolated and cultured cells was extracted with TRI Reagent (Euromedex, Bas-Rhin, France). Reverse transcription was performed from 1 mg of total RNA by using the Maxima First Strand cDNA kit with dsDNAse (Life Technologies), according to the manufacturer's instructions. CXCL10, MMP9, CXCR3A, and CXCR3B gene expression was analyzed by using real-time PCR with Platinum SYBR Green qPCR SuperMix-UDG kit (Invitrogen, Carlsbad, Calif) on the LightCycler system (Roche Diagnostics, Mannheim, Germany). Relative quantification was performed with b 2 -microglobulin as a reference gene.
CXCL10 expression in patients with BP
CXCL10 expression was analyzed in situ by means of immunohistochemistry and in biological fluids by using ELISA. Detailed procedures for analysis with immunohistochemistry and ELISA are described in the Methods section in this article's Online Repository at www.jacionline.org.
Zymography
MMP-9 levels were determined on conditioned media by using the zymography technique. Briefly, samples were electrophoresed on a 10% SDS polyacrylamide gel impregnated with 0.1% gelatin as substrate under nonreducing conditions. 34 The gels were subsequently fixed and stained with 0.25% Coomassie brilliant blue R-250 to visualize the proteolytic activity bands. Quantification was performed with ImageJ software (National Institutes of Health, Bethesda, Md).
Western blot and signaling assays
Nuclear and cytoplasmic extracts from CXCL10-stimulated THP-1 cells were prepared, as described by Antonicelli et al. 35 Both were separated on SDS polyacrylamide gel and transferred to a Hybond-ECL nitrocellulose membrane (GE Healthcare Biosciences, Fairfield, Conn). Membranes were incubated with the following primary antibodies: rabbit anti-nuclear factor kB (NF-kB) p50 (H-119), mouse anti-NF-kB p65 (F-6) , rabbit anti-phospho-p38, goat anti-lamin B (Santa Cruz Biotechnology, Dallas, Tex), anti-a-tubulin (Merck Millipore), rabbit anti-phospho-AKT, rabbit anti-phospho-extracellular signal-regulated kinase (ERK) 1/2, rabbit anti-AKT, and rabbit anti-ERK1/2 (Cell Signaling Technology, Danvers, Mass). Immunoreactivity was visualized by means of enhanced chemiluminescence (ECL or ECL Plus Western Blotting System, GE Healthcare Biosciences). (Fig 1, D) , serum-and BF-induced PBMCs from, healthy subjects (Fig 1, E) , and cytokinestimulated BP monocyte-derived macrophages (Fig 1, F) . **P < .01 and ***P < .001.
Statistical analysis
Descriptive statistics, such as means, SDs, or SEMs were conducted for all quantitative measures. Because the distribution of the CXCL10 concentration in serum and BF could not be assumed to be normal in this study, we used nonparametric testing to compare populations (Mann-Whitney and Wilcoxon tests). Two-way ANOVA was used to analyze the effect of CXCL10 treatment on MMP-9 activity in PMNs, PBMCs, monocytes, and lymphocytes isolated from control subjects or patients with BP. The results were considered significant if P values were .05 or less.
RESULTS
CXCL10 was highly expressed in blister fluid of patients with BP
Immunohistochemistry experiments on 16 skin biopsy specimens from patients with BP showed expression of CXCL10 by infiltrated cells, which were located both at the dermal-epidermal junction and in blister fluid (Fig 1, A) . Concomitant to CXCL10 expression, infiltrating cells within the lesional skin also expressed the CXCL10 receptor CXCR3 (Fig 1, A) . CXCL10 and CXCR3, which were detected in most of the biopsy specimens (Table I) , were also expressed by skin-resident cells, such as keratinocytes and fibroblasts (Table I and see Fig E1 in this article's Online Repository at www.jacionline.org). CXCL10 and CXCR3 expressions by inflammatory cells were concomitant to those observed in resident cells (Table I) . Using a specific ELISA test, higher concentrations of CXCL10 were measured in blister fluid (711 6 100 pg/mL, n 5 23) compared with serum (162 6 21 pg/mL, n 5 114) from patients with BP (P < .0001; Fig 1, B) , which were themselves even higher than CXCL10 concentrations in serum from age-and sex-matched control subjects (67 6 10 pg/mL; P 5 .004, n 5 34). At baseline, CXCL10 concentrations varied according to neither disease extent nor disease outcome (Table II) . 16 On the basis of our previous studies on BP autoantibodies 1 and IL-17 and IL-23 cytokines 6 during patient follow-up, we investigated the relevance of measuring variations in CXCL10 concentrations in the serum of patients with BP at days 0 and 60 for patients for whom serum samples were available (n 5 96). The clinical characteristics of this subgroup of patients with BP were similar to those of the whole studied population in terms of sex ratio, mean age, percentage of patients with extensive versus moderate disease, and rate of BP relapse within the first year of treatment (data not shown). Although BP was clinically controlled in all patients, the serum concentration of CXCL10 significantly increased between days 0 and 60 (n 5 33; 139 6 27 vs 221 6 43 pg/mL; P 5 .003) in the population of patients with BP who relapsed within the first year of treatment, whereas such variation did not occur in the population of patients with BP in remission (Fig 1, C) . Using blood cells from patients with BP, we showed that IL-17 increased CXCL10 mRNA expression from lymphocytes and that CXCL10 itself could increase its own expression in monocytes (2 of 4 patients with BP; Fig 1, D) . Accordingly, at the time of diagnosis and after 2 months of treatment, nearly all patients expressing IL-17 also expressed CXCL10 in their serum, and this occurred whatever the outcome of the disease (Fig 2) . 
111, Very highly expressed; 11, highly expressed; 1, expressed; 1/2, poorly expressed; 2, not expressed. To determine whether leukocytes required to be preactivated within the serum to later produce CXCL10 at sites of cutaneous lesions, we used our BP-related transdifferentiation cell model from blood to lesional skin. 5 To that end, PBMCs were isolated from healthy subjects (n 5 5) incubated consecutively with serum (BP vs autologous) for 48 hours and with blister fluid from patients with BP for an additional 48 hours (Fig 1, E) . Cells stimulated with serum from patients with BP or autologous serum alone did not show any significant variation in CXCL10 expression (Fig 1, E, higher panel) . When blister fluid was consecutively added to cells initially stimulated with autologous serum, the increase in CXCL10 expression was not consistent (Fig 1, E, middle  panel) . In contrast, consecutive PBMC stimulation with serum and blister fluid from patients with BP induced a substantial increase in CXCL10 expression in nearly all cases (Fig 1, E, lower  panel) . Indeed, consecutive stimulation of autologous or BP serum-treated PBMCs by blister fluid from patients with BP induced CXCL10 expression by 3.5 6 2.6 and 22.6 6 16.3, respectively (mean 6 SEM). In this line monocyte-derived macrophages upon serum stimulation expressed higher CXCL10 J ALLERGY CLIN IMMUNOL VOLUME 139, NUMBER 3 levels when stimulated with IL-17 (Fig 1, F) . The effects of IL-23 and CXCL10 itself on CXCL10 expression were patient dependent (Fig 1, F) . Together, these results suggested that systemic inflammation increases CXCL10 production from circulating cells and induces a preactivation state in those circulating leukocytes that favors their responses to cytokines/chemokines from blister fluid to produce CXCL10 in situ.
CXCL10 induced MMP-9 expression from monocytes and neutrophils
We then wondered whether CXCL10 could increase MMP-9 expression from both PBMCs and PMN cells originating from either healthy subjects or patients with BP. CXCL10 (500 pg/mL) significantly increased MMP-9 secretion from both PBMCs and PMN cells isolated from patients with BP but not from healthy control subjects (Fig 3) , confirming the prerequisite of a preactivation step for leukocytes in patients with BP to later respond to proinflammatory stimuli. In addition, CXCL10 increased MMP-9 secretion under both the zymogen and active forms in PBMCs from patients with BP, as demonstrated on gel zymography (Fig 3, A) .
We then investigated whether both lymphocytes and monocytes could secrete MMP-9 in response to CXCL10. Lymphocytes or monocytes purified from both patients with BP and healthy donors were stimulated similarly to PBMCs with CXCL10 at a concentration of 500 pg/mL. As shown in Fig 4, only monocytes from patients with BP displayed a significantly increased secretion of activated MMP-9 upon CXCL10 stimulation (n 5 7). This effect was associated with an increased MMP9 mRNA level when analyzed in 4 consecutive patients with BP (Fig 4, D) .
CXCR3 expression was not the limiting factor controlling CXCL10-induced MMP-9 production
We then wondered whether the differential MMP-9 expression observed between control subjects and patients with BP, as well as between lymphocytes and monocytes, could be related to the level of CXCL10 receptor expression (Fig 5) . Analysis of both CXCR3A and CXCR3B mRNA expression did not reveal any significant variations between control subjects and patients with BP in either lymphocytes or monocytes. However, the ratio of the 2 CXCR3 isoforms appeared to be inversed between lymphocytes and monocytes both in patients with BP and control subjects. CXCR3B mRNA was similarly expressed in lymphocytes and monocytes, whereas CXCR3A mRNA was significantly more expressed in lymphocytes than monocytes (P 5 .0015). The overexpression of either CXCR3A or CXCR3B was performed in the monocyte-derived cell line THP-1 to further investigate the role of these receptors in MMP-9 expression upon CXCL10 stimulation (see Fig E2 in this article's Online Repository at www.jacionline.org). Overexpression of each CXCR3 isoform increased MMP-9 secretion in response to CXCL10.
To further investigate the mechanisms associated with MMP-9 expression upon CXCL10 stimulation, we investigated several signaling pathways connected to CXCR3A and CXCR3B activation (Fig 6) . Kinetics analysis of untransfected THP-1 cells revealed that all signaling cascades investigated (ERK1/2, p38, phosphoinositide-3 kinase [PI3K]/AKT, and NF-kB) were activated after CXCL10 stimulation, although to different degrees (Fig 6, A) . Signaling pathway activation was observed either through protein phosphorylation (ERK1/2, p38, and PI3K/ AKT) or protein translocation from cytoplasm to nucleus (NF-kB). Nonphosphorylated forms, a-tubulin and lamin B, were used as loading controls. CXCL10 increased AKT phosphorylation after 1 hour and ERK1/2 and p38 phosphorylation after 4 hours of cell stimulation. CXCL10 also induced partly but time dependently the translocation of the p65 subunit of NF-kB from the cytosolic to the nuclear fraction, therefore increasing the proportion of the nuclear active p50/p65 heterodimer of this transcription factor, although most of these subunits remained inactive in the cytoplasm. The use of specific inhibitors for these signaling pathways showed the prevailing role of the ERK1/2 (U016), p38 (SB203580), and PI3K/AKT (LY294002) signaling pathways over NF-kB (SN50) in the upregulation of MMP-9 in monocytes (Fig 6, B) . Meanwhile, p38 and PI3K/AKT, but neither ERK1/2 nor NF-kB, signaling pathways were involved in MMP-9 production from CXCL10-stimulated PMN cells isolated from patients with BP (Fig 6,  B) . The use of methylprednisolone and a novel glucocorticoid receptor ligand (compound A) dose-dependently inhibited (Fig 3, B) and PBMCs (Fig 3, C) . Error bars denote means 6 SEMs, and 2-way ANOVA was used for statistics. *P < .05 and **P < .01. ns, Not significant. CXCL10-induced MMP-9 secretion from the monocytic cell line (Fig 6, C) .
DISCUSSION
Supporting the importance of the inflammatory response in patients with BP, we showed an increase in CXCL10 expression in body fluids and skin tissue from patients with BP compared with that seen in age-and sex-matched control subjects. CXCL10 levels were further enhanced in the serum of patients with BP who experienced a relapse during the first year of treatment. Of note, monocytes, but not lymphocytes, from patients with BP responded to CXCL10 by secreting higher levels of activated MMP-9, demonstrating a new inflammatory cascade implicated in the pathophysiology of the disease. Of note, CXCL10 expression could be enhanced by itself and IL-17 in monocytes and lymphocytes isolated from patients with BP, respectively, potentially creating an amplification mechanism of the inflammatory response in patients with BP.
At the time of diagnosis, CXCL10 concentrations were increased in the serum of patients with BP with respect to those in age-and sex-matched control subjects, but this was informative of neither disease severity nor later disease relapse. Then our results at baseline did not confirm a previous study performed on a smaller series, suggesting that the serum level of CXCL10 was associated with disease severity. 12 This discrepancy might rely on the different approaches of disease severity determination because Nakashima et al 12 studied CXCL10 levels with respect to the body surface affected, whereas we investigated CXCL10 level with respect to the number of daily blisters. Therefore further studies should be performed by using the Bullous Pemphigoid Disease Area Index score 36 to better elucidate the relationship between CXCL10 concentration and disease activity. Nevertheless, our longitudinal analysis revealed that CXCL10 levels further increased at day 60 after the first 2 months of treatment in patients with BP who later relapsed, although they all experienced clinical control on therapy within the first 2 months of treatment. This supports our previous study showing that serum contains markers of disease outcome, such as BP180 autoantibodies, 1 IL-17, and IL-23. 6 Here we showed that variation in the CXCL10 serum concentration is also a marker of BP outcome.
CXCL10 was highly expressed in lesional skin of patients with BP. Both inflammatory infiltrating cells and skin-resident cells (keratinocytes, fibroblasts, and endothelial cells) produced CXCL10. Therefore our results are in line with previous studies showing that CXCL10 is produced by a large variety of cell types (Fig 4, B) and monocytes (Fig 4, C) . D, CXCL10-induced MMP9 mRNA expression in monocytes from healthy control subjects and patients with BP. *P < .05. ns, Not significant.
in both patients with organ-specific and those with systemic autoimmune diseases. 11, 14 In patients with those autoimmune diseases, CXCL10 expression was upregulated after cell stimulation with IFN-g and further enhanced when costimulated with TNFa, 11, 14 2 cytokines overexpressed at the site of lesions in patients with BP. 37 In addition to these cytokines, we showed that IL-17, another inflammatory cytokine largely expressed in blister fluid from patients with BP, 5 also increased CXCL10 expression in monocyte-derived macrophages issued from patients with BP. Of note, IL-17 was shown to induce CXCL10 expression by keratinocytes. 38 Accordingly, high expression of CXCL10 by infiltrating cells was almost always concomitant to high expression of CXCL10 by skin-resident cells. This suggests an important role of IL-17 in CXCL10 production in lesional skin from patients with BP and could explain the large amount of CXCL10 detected in the blister fluid at time of diagnosis. In this setting the BF/serum ratio would rather favor a tissue local synthesis of CXCL10 by influxed inflammatory cells, as well as by keratinocytes and fibroblasts, during the onset of the active disease. However, skin from patients with BP is rapidly cleared of all clinical signs under treatment. Therefore one can assume that the main source of sustained or even increased CXCL10 serum concentrations observed in some patients with BP is more likely related to circulating cells.
Indeed, we observed that CXCL10 expression could be upregulated by itself and by IL-17, respectively, in monocytes and lymphocytes isolated from patients with BP. Such a dual trigger could be a requirement for the formation of an amplification feedback loop and the perpetuation of the autoinflammatory process. This need for a costimulatory effect could reflect immune cell interplay and explain why CXCL10 concentrations only increase in serum of patients with BP who will relapse during the first year of treatment but not in those of patients with BP with ongoing remission. Indeed, we have previously shown that sustained IL-17 and IL-23 concentrations occurred only in patients with BP who later had a relapse. 6 Therefore it appears very important to determine the orchestrated network of chemokines and cytokines that contributes to the pathophysiologic mechanisms of BP progress.
CXCL10 increased MMP-9 secretion from monocytes and neutrophils but not from lymphocytes. Such an effect, observed with cells isolated from patients with BP but not healthy donors, could not be explained by the difference in expression of CXCR3 isoforms. Interestingly, monocytes responded to CXCL10 to produce both MMP-9. Such responsiveness could be related to the fact that monocytes from patients with BP are preactivated by a network of inflammatory molecules released by different types of circulating immune cells. In this line it was shown that CD14 1 CD56 1 monocytes also expressing CD16 were more prone to express inflammatory cytokines, such as IL-1b and IL-23, and were expanded in conditions associated with inflammatory and autoimmune diseases. [39] [40] [41] Although this monocyte subset still need to be investigated in patients with BP, one can notice that IL-23 is overexpressed in the serum of patients with BP compared with expression in age-and sexmatched control subjects and is even increased in the serum of patients with BP who later experience a relapse. 6 Because CXCL10 increases its own production by monocytes in some patients with BP, this could further amplify MMP-9 production in those patients. Furthermore, it was shown that CD16/FcgRIII mediates tissue destruction in a mouse model of BP, 42 which fits with the fact that CXCL10 induced MMP-9 expression from monocytes and neutrophils, as well as human leukocyte elastase activity from neutrophils (approximately 2.5-fold, data not shown), 2 proteinases involved in blister formation. Therefore, like IL-17 and IL-23, 6 CXCL10 could enhance tissue damage, feeding the autoimmune process thereof. Subsequently, the inhibition of CXCL10-induced proteases would certainly help to control BP progression.
It is of interest that the use of compound A, a selective glucocorticoid receptor activator ligand that preserves the therapeutic effect of glucocorticoids with fewer adverse effects, 33 was as effective as methylprednisolone in inhibiting CXCL10-induced MMP-9. Accordingly, compound A was shown to inhibit the activation of several transcription factors, such as activator protein 1, involved in MMP-9 expression by suppressing activation of the PI3K/Akt and ERK1/2 signaling cascades. 43 However, it remains to be determined whether such treatment could be effective in reducing CXCL10-induced MMP-9 in vivo and whether its efficiency varies according to BP outcome.
In conclusion, our study further documents the inflammatory responses in patients with BP and showed that CXCL10 level determination should be included in the inflammatory molecule panel constituting the BP ''inflammascore'' we previously proposed. 6 We also provide new evidence that monocyte preactivation by inflammatory molecules in serum of patients with BP could be crucial in the pathophysiologic process of BP. Finally, we showed that it is worth paying attention to selective glucocorticoid receptor activators, such as compound A, which might be potentially useful in reducing the numerous adverse events and glucocorticoid resistance induced by classical corticosteroid treatment of patients with BP.
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Key messages
d BP relapse is associated with an increase in CXCL10 concentration.
d In patients with BP, neutrophils and monocytes, but not lymphocytes, responded to CXCL10 by increasing MMP-9 release, potentially creating an inflammatory loop associated with disease outcome.
d Compound A, a novel nonsteroidal glucocorticoid receptor ligand, inhibited CXCL10-induced MMP-9 secretion.
FIG E1. CXCL10 expression in nonimmune resident cells at the lesion site in patients with BP. CXCL10, as analyzed by using immunohistochemistry (IHC), was expressed by keratinocytes (indicated by arrowheads in A) and fibroblasts and vascular cells (indicated by arrowheads and the arrow, respectively, in B) at the lesion site in skin biopsy specimens from patients with BP.
